Similarly, a HER2-targeted ADC carrying a Toll-like receptor 7 (TLR7) agonist activates innate immune responses within tumors, inducing tumor regression through immune stimulation rather than direct cytotoxicity [51]. This evidence concerns the gene ERBB2 and neoplasm.